Clarity Pharmaceuticals says it will be 'unaffected' by US pharma tariffs
Make us a preferred source
Make us a preferred source on Google
The news: Clarity Pharmaceuticals said it will remain unaffected by US President Donald Trump's 100% tariff on imports of branded pharmaceutical products, that is set to take effect from 1 October.
The numbers: Clarity shares initially fell in early trade but were up 0.8% to $3.77 by 1:30pm AEST, having dropped 56.7% over the last 12 months.
The context: The biotech also confirmed that all of its isotope and drug product manufacturers for its US clinical trial sites are located in the US.
Clarity — a clinical-stage radiopharmaceutical company focused on the treatment of serious diseases — said it is aiming to build a supply chain that is "impervious to current political dynamics".
What they said: "Clarity's products, from isotope manufacture to finished product, are made in America for Americans," said the company's executive chair Alan Taylor.
"... We look forward to continuing our US-focused commercialisation strategy, working with our key US partners and clinical sites as we quickly progress our products to market in pursuit of our ultimate goal of better treating people with cancer."
The source: ASX
